Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.
Adult
Aged
Disease-Free Survival
Female
Glioblastoma
/ mortality
Humans
Immunotherapy
/ methods
Immunotoxins
/ pharmacology
Interleukin-4 Receptor alpha Subunit
/ antagonists & inhibitors
Male
Middle Aged
Neoplasm Recurrence, Local
/ mortality
Nervous System Neoplasms
/ drug therapy
Prospective Studies
Survival Rate
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
received:
03
02
2021
revised:
16
03
2021
accepted:
13
04
2021
pubmed:
18
4
2021
medline:
1
4
2022
entrez:
17
4
2021
Statut:
ppublish
Résumé
The current study compared the standard response assessment in neuro-oncology (RANO), immunotherapy RANO (iRANO), and modified RANO (mRANO) criteria as well as quantified the association between progression-free (PFS) and overall survival (OS) in an immunotherapy trial in recurrent glioblastoma (rGBM). A total of 47 patients with rGBM were enrolled in a prospective phase II convection-enhanced delivery of an IL4R-targeted immunotoxin (MDNA55-05, NCT02858895). Bidirectional tumor measurements were created by local sites and centrally by an independent radiologic faculty, then standard RANO, iRANO, and mRANO criteria were applied. A total of 41 of 47 patients (mean age 56 ± 11.7) were evaluable for response. PFS was significantly shorter using standard RANO compared with iRANO (log-rank, No correlation between radiographic PFS and OS was observed for standard RANO or iRANO, but a correlation was observed between PFS and OS using the mRANO criteria. Also, the iRANO criteria was difficult to implement due to need to confirm progression 3 months after initial progression, censoring more than half the patients.
Identifiants
pubmed: 33863808
pii: 1078-0432.CCR-21-0446
doi: 10.1158/1078-0432.CCR-21-0446
pmc: PMC8282697
mid: NIHMS1696668
doi:
Substances chimiques
IL4R protein, human
0
Immunotoxins
0
Interleukin-4 Receptor alpha Subunit
0
Banques de données
ClinicalTrials.gov
['NCT02858895']
Types de publication
Clinical Trial, Phase II
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3916-3925Subventions
Organisme : NCI NIH HHS
ID : R21 CA223757
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : EPA
ID : EP-C-15-003
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227136
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS079697
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
J Neurooncol. 2004 Jan;66(1-2):197-201
pubmed: 15015787
Toxins (Basel). 2019 Jan 05;11(1):
pubmed: 30621280
J Clin Oncol. 2013 Sep 10;31(26):3212-8
pubmed: 23940216
AJNR Am J Neuroradiol. 2001 Sep;22(8):1517-27
pubmed: 11559499
J Mol Biol. 2001 Dec 7;314(4):823-37
pubmed: 11734000
J Clin Oncol. 2007 Aug 1;25(22):3357-61
pubmed: 17664483
BMC Cancer. 2010 Feb 02;10:30
pubmed: 20122270
Neuro Oncol. 2015 Jan;17(1):151-9
pubmed: 25038253
Neurotherapeutics. 2017 Apr;14(2):307-320
pubmed: 28108885
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Lancet Oncol. 2015 Nov;16(15):e534-e542
pubmed: 26545842
Cancer. 2008 Mar 1;112(5):1139-46
pubmed: 18246536
Neuro Oncol. 2015 Sep;17(9):1188-98
pubmed: 26250565
J Clin Oncol. 2010 Mar 1;28(7):1168-74
pubmed: 20124186
Neurology. 2004 Oct 12;63(7):1281-4
pubmed: 15477552
Neuro Oncol. 2014 Mar;16(3):414-20
pubmed: 24305712
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Medicine (Baltimore). 2019 Dec;98(50):e18194
pubmed: 31852075
Neuro Oncol. 2013 Jan;15(1):4-27
pubmed: 23136223